Recurrence of pemphigus vulgaris associated with interleukin 2 therapy.
BACKGROUND
Immunotherapy with recombinant interleukin 2 may result in regression of metastatic cancer, particularly malignant melanoma and renal cell carcinoma.


METHODS
We describe a patient who received interleukin 2 immunotherapy for metastatic renal cell carcinoma. After his second course of treatment, he developed a recurrence of pemphigus vulgaris that had been in remission for 10 years.


CONCLUSIONS
Interleukin 2 therapy may be associated with recurrence of an autoimmune disease, perhaps because of its ability to stimulate autoantibody production.
Prussick
R
R
Dermatology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Md.
Plott
R T
RT
Stanley
J R
JR
D000368:Aged; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000556:secondary; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology; D008297:Male; D010392:Pemphigus / Q000209:etiology* / Q000276:immunology; D012008:Recurrence
D007376:Interleukin-2